



## INTRODUCTION

- Pancreatic ductal adenocarcinoma (PDAC) 4<sup>th</sup> leading cause of cancer deaths.
- PDAC presents at late stage and is refractory to most treatment modalities.
- Low tumor cellularity and high desmoplastic response makes *in vitro* study difficult, but several mutations have been identified.
- Wnt signaling, activated by pancreatic ductal ligation injury, plays a critical role in proliferation and chemotherapeutic resistance. Wnt signaling, therefore, may serve as a potential therapeutic target.
- Pancreatic tumor organoid libraries (PTOL) allow for accurate investigation of other therapies.

## MATERIALS AND METHODS

- Seven PDAC organoids grown in Human Pancreatic Stem Cell medium.
- Minimal media conditions required to maintain growth assessed with depletion of the various niche factors Wnt3a, EGF, Noggin, R-spondin, ALK inhibitor, or p38 inhibitor.
- Confirmation of Wnt inhibition by growing organoids in minimal media and treating with Wnt inhibitors ICG001, ETC159, C59.
- Growth assessed with CellTiter Glo 3D.
- Tumors injected into athymic nude mice and treated for 30 days with assessment of growth rate and tumor regrowth following removal of drug
- Gene signatures for respective organoid and PDX models were determined through RNA-seq
- RT-PCR performed for human Wnt genes

## OBJECTIVE

- Subclassify PDAC organoids based on Wnt dependency to determine if combinatory treatment with Wnt inhibitors and chemotherapy would serve as a feasible treatment.

## PATHWAYS






Figure 3: *In Vivo* Combinatory Drug Treatment

## CONCLUSIONS

- Each organoid demonstrated different niche factor dependencies, providing an avenue for targeted therapy, particularly Wnt inhibition.
- Combinatory treatment with Wnt inhibition and chemotherapy *in vitro* and in patient-derived xenograft models suggests beneficial application of combinatory treatment
- Gene signature and expression analysis of each organoid suggests correlation between genotype and Wnt (in)dependency observed *in vitro*.

## References

- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. *CA Cancer J Clin*. Jan 2021;71(1):7-33. doi:10.3322/caac.21654
- Seino T, Kawasaki S, Shimokawa M, et al. Human Pancreatic Tumor Organoids Reveal Loss of Stem Cell Niche Factor Dependence during Disease Progression. *Cell Stem Cell*. 2018;22(3):454-467.e6. doi:10.1016/j.stem.2017.12.009
- Sato T, Stange DE, Ferrante M, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. *Gastroenterology*. Nov 2011;141(5):1762-72. doi:10.1053/j.gastro.2011.07.050
- Madan B, Ke Z, Harmston N, et al. Wnt addiction of genetically defined cancers reversed by PORCN inhibition. *Oncogene*. Apr 28 2016;35(17):2197-207. doi:10.1038/ncr.2015.280




Figure 1: Pancreatic organoids growth factor dependency and confirmation of Wnt dependency through the utilization of Wnt pathway inhibitors: ICG001, ETC159, C59.




Figure 4: RT-PCR gene expression analysis of organoids post-treatment for key genes contributing to Wnt dependency as described by Madan et al.




Figure 2: Wnt (in)dependency gene signatures according to those identified by Seino et al.




Figure 5: Heat map of Wnt gene fold change expression for post-treated pancreatic tumors

## ACKNOWLEDGEMENTS

Special thanks to the Wings of Hope for Pancreatic Cancer Research for their generous contribution, Dr. Todd Pitts and Dr. Peter Dempsey, the University of Colorado Cancer Center, and the University of Colorado Anschutz.

